# Amgen Inc.

Canonical: https://abierto.us/vendors/amgen-inc-d92harf1lka9

- UEI: D92HARF1LKA9
- CAGE: 0JVZ6
- Location: Thousand Oaks, CA
- Awards in window: 2 (3 transactions), $2,276,291 obligated, May 1, 2024 to June 2, 2026

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 2 awards, $2,276,291

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $2,276,291
- 325412 Pharmaceutical Preparation Manufacturing: $0

## Competition

- Full and Open Competition: 1 awards
- Not Competed: 1 awards

## Largest awards

- 75A50119C00061 (definitive contract): $2,276,291, Barda - Aspr / Daappo / Barda DCMA. No Cost Modification to Revise the Pop Within Prism to Match Bilateral Modification Dates.. https://www.usaspending.gov/award/CONT_AWD_75A50119C00061_7505_-NONE-_-NONE-/
- 75A50123C00040 (definitive contract): $0, Barda - Aspr / Daappo / Barda DCMA. No Cost Extension Clin 0001. Period of Performance for Clin 0001 Ends 28 June 2028. Revise B.6 Advance Understandings and Revise Section G to Add Alternate Cor, and Revise Section I Contract Clauses. Clause Required from Eo 14398 Included.. https://www.usaspending.gov/award/CONT_AWD_75A50123C00040_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/amgen-inc-d92harf1lka9.